Pantop%2525252525252525252525252525252525252520d

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase enzyme system in the gastric parietal cell. ## Primary Indications * Short-term treatment of erosive esophagitis associated with GERD. * Maintenance of healing of erosive esophagitis. * Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome). * Prophylaxis of stress-related mucosal injury (stress ulcers) in critically ill patients. ## Adult Dosing * **GERD/Erosive Esophagitis:** 40 mg PO or IV once daily for up to 8 weeks. * **Maintenance of Healing:** 40 mg PO daily. * **Hypersecretory Conditions:** Starting dose 40 mg PO twice daily; titrate based on clinical need. Doses up to 240 mg/day have been used. * **Stress Ulcer Prophylaxis:** 40 mg IV daily. ## Pediatric Dosing * **Pediatric GERD (5 years and older):** * 15 kg to <40 kg: 20 mg PO once daily. * ≥40 kg: 40 mg PO once daily. * *Note: Safety and efficacy for children <5 years have not been established.* ## Dose Adjustments * **Hepatic Impairment:** No specific adjustment required for mild to moderate impairment; caution advised. Severe impairment may require dose reduction or reduced frequency. * **Renal Impairment:** No dosage adjustment necessary. * **Elderly:** No dosage adjustment necessary. ## Contraindications * Hypersensitivity to pantoprazole or any component of the formulation. * Concomitant use with rilpivirine-containing products. ## Adverse Effects * **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence. * **Serious:** *Clostridioides difficile*-associated diarrhea, hypomagnesemia, vitamin B12 deficiency (long-term use), acute interstitial nephritis, cutaneous/systemic lupus erythematosus, bone fractures (long-term use). ## Key Drug Interactions * **pH-Dependent Drugs:** May decrease absorption of ketoconazole, iron salts, and mycophenolate mofetil. * **Warfarin:** Theoretical increased risk of elevated INR/bleeding; monitor closely. * **Methotrexate:** May increase serum levels of methotrexate, particularly in high-dose therapy. ## Monitoring * Monitor for signs of *C. difficile* infection (e.g., persistent watery diarrhea). * For long-term therapy: Monitor serum magnesium and Vitamin B12 levels. * Monitor renal function if acute interstitial nephritis is suspected. ## Clinical Pearls * **Administration:** PO tablets should be swallowed whole; do not crush or chew. IV administration should be performed as a slow injection or infusion to avoid vein irritation. * **De-prescribing:** Always evaluate the necessity of PPI therapy; many patients are maintained on PPIs without a clear indication, increasing the risk of adverse effects. * **Protocol Dependency:** Dosing for stress ulcer prophylaxis and hypersecretory conditions often follows weight-based or institutional-specific protocols; always consult local pharmacy guidelines. *** **Disclaimer:** This information is for educational purposes only. Clinical practice guidelines change frequently; always verify dosage, contraindications, and potential drug interactions with current, institution-approved prescribing resources or official FDA-approved labeling before administration.